Biologics Fermentation Capacity Market (2026-2036)
The global biologics fermentation capacity market is projected to reach USD 32.4 billion by 2036 from an estimated USD 9.85 billion in 2026, at a CAGR of 12.6% during the forecast period from 2026 to 2036.
- Published
- Sep 2026
- Pages
- 308
- Format
- PDF + Excel
- Report ID
- MR-2165
- Base year
- 2025
- 2026 · ESTIMATED
- $9.85B
- 2036
- $32.40B
- CAGR 2026–2036
- 12.6%
2025 baseline · 2026–2036 forecast at 12.6% CAGR · hover a bar for the value
Key highlights
The global biologics fermentation capacity market is projected to reach USD 32.4 billion by 2036, growing at a CAGR of 12.6% during 2026–2036, driven by a record biologics pipeline, rapid adoption of single-use and modular bioprocessing technology, and government-backed reshoring of domestic biomanufacturing capacity.
The FDA's Center for Biologics Evaluation and Research approved 24 new Biologics License Applications in 2024, extending a multi-year climb from 12 and 13 approvals in 2021 and 2022, and included a record 13 new monoclonal antibodies, underscoring the growing volume of biologics requiring fermentation and cell culture capacity.
The competitive landscape spans established bioprocess equipment manufacturers including Sartorius AG, Cytiva (Danaher Corporation), Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), Eppendorf SE, ABEC, PBS Biotech, Getinge (Applikon Biotechnology), Distek, Cellexus, Solaris Biotech, INFORS HT, Bioengineering AG, GEA Group, ZETA, and Pierre Guerin, each expanding single-use, stainless-steel, and hybrid bioreactor portfolios.
Thermo Fisher Scientific introduced its 5-liter DynaDrive single-use bioreactor in February 2026 for small-scale, GMP-ready bioprocessing, while Cytiva expanded its Xcellerex platform with 500-liter and 2,000-liter single-use systems in March 2025, illustrating continued platform broadening across scales.
The National Institute for Innovation in Manufacturing Biopharmaceuticals, a public-private partnership operating under a cooperative agreement with the U.S. National Institute of Standards and Technology, has awarded more than USD 111 million across over 120 biopharmaceutical manufacturing technology and workforce projects since its 2017 launch, including a testbed facility advancing continuous bioprocessing.
The European Commission proposed the European Biotech Act on December 16, 2025, alongside the earlier Critical Medicines Act of March 2025, both aimed at expanding EU biomanufacturing capacity through fast-tracked permitting, streamlined environmental assessments, and targeted financial support for strategic manufacturing projects.
India's Department of Pharmaceuticals operates a dedicated Production Linked Incentive Scheme for Bulk Drugs with a financial outlay of ₹6,940 crore, requiring a minimum domestic value addition of 90% for fermentation-based products and covering fermentation-based antibiotics such as erythromycin, neomycin, and gentamicin, though disbursement under the fermentation-heavy bulk drugs component has lagged the broader pharmaceuticals scheme.
FUJIFILM Diosynth Biotechnologies is expanding its Hillerød, Denmark site to twelve 20,000-liter mammalian cell bioreactors with integrated fill-finish capability, one of the largest single biologics drug substance capacity investments underway in Europe.
North America and Europe together hold the largest revenue share in 2026, supported by dense CDMO networks and regulatory approval volumes, while Asia-Pacific is expected to register the fastest CAGR on the back of large-scale capacity build-out in China and South Korea and national bulk drug and biopharma manufacturing incentive programmes in India.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026–2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 12.6% |
| Format | PDF, Excel & Cloud Portal · 308 pages |
| Market Size (Value) in 2026 | USD 9.85 Billion |
| Market Size (Value) in 2036 | USD 32.4 Billion |
| Segments Covered | By System Type: Single-Use Bioreactor Systems; Stainless Steel/Reusable Bioreactor Systems; Hybrid Systems. By Scale of Operation: Bench & Pilot Scale; Clinical Scale; Commercial/Large Scale. By Mode of Operation: Batch; Fed-Batch; Perfusion/Continuous. By Cell/Organism Type: Mammalian Cell Culture; Microbial Fermentation; Others. By Application: Monoclonal Antibodies & Biosimilars; Vaccines; Cell & Gene Therapy; Recombinant Proteins & Enzymes. By End User: CDMOs/CMOs; Biopharmaceutical & Biotechnology Companies; Academic & Research Institutes |
| Countries Covered | North America (U.S., Canada), Europe (Germany, U.K., France, Denmark, Switzerland, Italy, Rest of Europe), Asia-Pacific (China, South Korea, India, Japan, Australia & New Zealand, Rest of Asia-Pacific), Latin America (Brazil, Argentina, Mexico, Rest of Latin America), and the Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of Middle East & Africa) |
| Key Companies | Sartorius AG (Germany), Danaher Corporation/Cytiva (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Eppendorf SE (Germany), ABEC, Inc. (U.S.), Getinge AB (Sweden), Tofflon Science and Technology Co., Ltd. (China), GEA Group Aktiengesellschaft (Germany), Pierre Guérin (France), ZETA GmbH (Austria), Bioengineering AG (Switzerland), INFORS HT (Switzerland), PBS Biotech, Inc. (U.S.), bbi-biotech GmbH (Germany), Solaris Biotech Solutions S.r.l. (Italy). |
| Primary Reference Sources | U.S. Food and Drug Administration, Center for Biologics Evaluation and Research (biologics approval data); National Institute for Innovation in Manufacturing Biopharmaceuticals, operating under cooperative agreement with the National Institute of Standards and Technology, U.S. Department of Commerce (manufacturing project investment data); European Commission (Critical Medicines Act and European Biotech Act proposals); Press Information Bureau and Department of Pharmaceuticals, Government of India (Production Linked Incentive Scheme data); company press releases, product documentation, and investor disclosures from Sartorius, Thermo Fisher Scientific, Cytiva/Danaher, Merck KGaA, ABEC, PBS Biotech, Getinge, FUJIFILM Diosynth Biotechnologies, and WuXi Biologics; and specialist trade press including BioProcess International and Fierce Pharma |
Report overview
Segments covered: system type, scale of operation, mode of operation, cell/organism type, application, end user. Regions: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
Single-use bioreactor systems account for the largest share of installed capacity additions through most of the forecast period, reflecting their lower capital intensity and faster commissioning timelines, while hybrid facility designs that combine single-use flexibility with stainless-steel scale represent the fastest-growing system category as large-scale commercial manufacturers balance speed-to-capacity with the economics of high-volume production.
Fermentation capacity refers to the installed base of bioreactor and fermenter systems, together with the associated upstream processing equipment, used to cultivate mammalian cells, bacteria, yeast, and other production organisms for manufacturing biologic drugs. The category covers classical stainless-steel, reusable bioreactor vessels engineered for large, dedicated commercial production; single-use or disposable bioreactor systems built around pre-sterilized polymer bags that eliminate cleaning and sterilization cycles between batches; and hybrid facility designs that combine both formats within the same manufacturing footprint. Fermentation capacity is installed to produce monoclonal antibodies and biosimilars, vaccines, recombinant proteins and enzymes, and a fast-growing set of cell and gene therapy products, using either mammalian cell culture platforms such as CHO and HEK293 cell lines or microbial fermentation platforms based on bacteria and yeast.
The category has moved well beyond the era when stainless-steel vessels were the default choice for any biologics facility. Sartorius, Cytiva, Thermo Fisher Scientific, and Merck KGaA now offer single-use bioreactor platforms spanning bench-scale development systems through multi-thousand-liter commercial production vessels, while specialist manufacturers such as ABEC, PBS Biotech, and Distek focus on custom, large-format single-use systems and vertical-wheel or advanced therapy-specific designs. At the same time, contract development and manufacturing organizations including FUJIFILM Diosynth Biotechnologies and WuXi Biologics continue to invest in very large stainless-steel and microbial fermenter capacity for high-volume commercial programmes, reflecting the reality that no single system type serves every stage of the biologics manufacturing lifecycle.
Demand for fermentation capacity is increasingly shaped by the sheer scale of the biologics pipeline rather than by any single therapeutic class. Regulatory approval volumes for monoclonal antibodies, biosimilars, and cell and gene therapies continue to climb, placing sustained pressure on both in-house biopharmaceutical manufacturers and outsourced CDMO networks to add fermentation capacity quickly and predictably. Government policy is reinforcing this pressure in several major markets, such as, the United States has directed public-private investment through NIIMBL into manufacturing technology and workforce readiness, the European Union has proposed the Critical Medicines Act and European Biotech Act to fast-track EU-based manufacturing capacity, and India has structured a dedicated incentive scheme for fermentation-based bulk drug production. These factors are expected to support strong, sustained growth in the biologics fermentation capacity market through 2036.
Report infographic
Market dynamics
9 factors across 5 forcesSurging Biologics Pipeline and Record Regulatory Approvals
The volume of biologics reaching regulatory approval has risen steadily over the past several years. The FDA's Center for Biologics Evaluation and Research approved 24 new Biologics License Applications in 2024, compared with 22 in 2023 and just 12 and 13 in 2021 and 2022, and monoclonal antibody approvals reached a record 13 molecules in 2024, the highest since 2015. Each newly approved biologic requires dedicated or shared fermentation capacity for both clinical supply and commercial launch, and this sustained approval volume is a direct structural driver of new bioreactor and fermenter installations across CDMOs and in-house manufacturers alike.
Rapid Adoption of Single-Use and Modular Bioprocessing Technology
Single-use bioreactor systems allow manufacturers to add fermentation capacity in months rather than the years typically required for stainless-steel facility construction, and equipment manufacturers have responded with an accelerating pace of platform launches. Thermo Fisher Scientific's February 2026 introduction of its 5-liter DynaDrive system, Cytiva's March 2025 expansion of the Xcellerex platform to 500-liter and 2,000-liter formats, and ABEC's 2025 launch of an advanced therapy-focused single-use bioreactor collectively illustrate how modular, disposable technology is becoming the default route for both new capacity and rapid capacity conversion.
Government-Backed Reshoring and Public-Private Investment in Domestic Biomanufacturing
Governments across major markets are treating biologics manufacturing capacity as a matter of supply security. In the United States, NIIMBL has channelled more than USD 111 million into biopharmaceutical manufacturing technology and workforce projects since 2017 under a cooperative agreement with NIST. In the European Union, the European Commission's Critical Medicines Act and the subsequently proposed European Biotech Act are designed to fast-track permitting and provide financial support for strategic EU manufacturing capacity projects. In India, the Department of Pharmaceuticals' Production Linked Incentive Scheme for Bulk Drugs specifically targets fermentation-based products, requiring 90% minimum domestic value addition for products manufactured through fermentation routes.
Table of contents
14 chapters · 124 sections · 308 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By System Type | Single-use bioreactor systems | While Hybrid Systems |
| By Scale of Operation | Commercial and large-scale systems | Bench & Pilot Scale |
| By Mode of Operation | Fed-batch operation | Perfusion/Continuous |
| By Cell/Organism Type | Mammalian cell culture | Microbial Fermentation |
| By Application | Monoclonal antibodies and biosimilars | Cell & Gene Therapy |
| By End User | CDMOs/CMOs | — |
By System Type
- Single-use bioreactor systems account for the largest share of new capacity additions, supported by lower upfront capital requirements and faster facility commissioning timelines from manufacturers such as Sartorius, Cytiva, and Thermo Fisher Scientific.
- Hybrid systems, which pair single-use flexibility with stainless-steel scale within the same facility, are projected to grow fastest as large commercial manufacturers such as FUJIFILM Diosynth Biotechnologies pursue blended capacity strategies.
By Scale of Operation
- Commercial/Large Scale Leads in 2026, Bench & Pilot Scale Grows Fastest
- Commercial and large-scale systems account for the largest share in 2026, reflecting the multi-thousand-liter bioreactor investments underway at CDMOs and large biopharmaceutical manufacturers.
- Bench and pilot scale systems are projected to grow fastest, driven by the expanding population of early-stage biotechnology companies and equipment launches such as Thermo Fisher Scientific's 5-liter DynaDrive system aimed at small-scale, GMP-ready bioprocessing.
By Mode of Operation
- Fed-Batch Leads in 2026, Perfusion/Continuous Grows Fastest
- Fed-batch operation accounts for the largest share in 2026, reflecting its established role as the standard mode for monoclonal antibody manufacturing.
- Perfusion and continuous processing are projected to grow fastest, supported by process intensification initiatives, including NIIMBL's continuous manufacturing testbed programme, that aim to increase output per unit of installed fermentation capacity.
By Cell/Organism Type
- Mammalian Cell Culture Leads in 2026, Microbial Fermentation Grows Fastest
- Mammalian cell culture accounts for the largest share in 2026, reflecting its central role in producing monoclonal antibodies and other glycosylation-dependent biologics.
- Microbial fermentation is projected to grow fastest, supported by its cost advantages for recombinant proteins, biosimilars, and fermentation-based bulk drugs, an area specifically targeted by India's Bulk Drugs PLI Scheme.
By Application
- Monoclonal Antibodies & Biosimilars Lead in 2026, Cell & Gene Therapy Grows Fastest
- Monoclonal antibodies and biosimilars account for the largest share of the market, consistent with the record 13 monoclonal antibody approvals recorded by the FDA in 2024.
- Cell and gene therapy is projected to grow fastest, supported by dedicated fermentation and bioreactor platforms such as ABEC's Advanced Therapy Bioreactor entering commercial use.
By End User
- CDMOs/CMOs Dominate the Market in 2026
- CDMOs and CMOs account for the largest share of the market driven by large-scale capacity investments such as FUJIFILM Diosynth Biotechnologies' Hillerød expansion and WuXi Biologics' Chengdu microbial manufacturing site.
- Biopharmaceutical and biotechnology companies building owned, in-house fermentation capacity are projected to register meaningful growth, supported by reshoring-oriented policy programmes including NIIMBL, the European Biotech Act, and India's Bulk Drugs PLI Scheme.
Geographic analysis
North America
North America holds a leading share in 2026, supported by the FDA's sustained pace of biologics approvals, a dense network of CDMOs and in-house biopharmaceutical manufacturers, and public-private capacity investment channelled through NIIMBL under its cooperative agreement with the National Institute of Standards and Technology.
Europe
Europe represents a major and increasingly policy-supported centre for fermentation capacity investment, anchored by large single-site expansions such as FUJIFILM Diosynth Biotechnologies' Hillerød, Denmark facility. The European Commission's Critical Medicines Act, proposed in March 2025, and the subsequently proposed European Biotech Act of December 2025 are both designed to fast-track permitting and provide targeted financial support for EU-based biomanufacturing capacity, reinforcing the region's strategic push toward manufacturing self-sufficiency.
Asia-Pacific
Fastest growthAsia-Pacific is expected to register the fastest CAGR during the forecast period, driven by large-scale capacity build-out in China, exemplified by WuXi Biologics' Chengdu microbial manufacturing site, continued expansion by South Korea's contract manufacturing base, and India's Department of Pharmaceuticals-administered Production Linked Incentive Scheme for Bulk Drugs, which specifically incentivizes fermentation-based production.
Latin America
Latin America and the Middle East & Africa remain earlier-stage markets, with growth concentrated in national health security and import-substitution initiatives for essential biologics and fermentation-based drugs.
Competitive landscape
Major companies in the global biologics fermentation capacity market have pursued platform innovation, capacity expansion, targeted acquisitions, and geographic diversification to strengthen their positions. Established bioprocess equipment manufacturers with global service networks compete alongside specialist single-use and modular system providers addressing next-generation modalities.
- —
Thermo Fisher Scientific introduced the 5-liter DynaDrive single-use bioreactor in February 2026, aimed at small-scale and academic GMP-ready bioprocessing.
- —
Cytiva expanded its Xcellerex platform in March 2025 with the addition of 500-liter and 2,000-liter single-use bioreactors to support monoclonal antibody and vaccine production.
- —
FUJIFILM Diosynth Biotechnologies launched the first phase of its Hillerød, Denmark expansion in November 2024, adding six mammalian cell bioreactors toward a site total of twelve 20,000-liter vessels with fill-finish capability.
- —
ABEC launched its Advanced Therapy Bioreactor in March 2025, a single-use system designed to mimic human circulation for scalable cell therapy manufacturing.
- —
PBS Biotech secured USD 17 million in funding in January 2025 from Avego Management and BroadOak Capital Partners to accelerate development of its Vertical-Wheel bioreactor platform.
- —
Merck KGaA's MilliporeSigma business launched a dedicated antibody-drug-conjugate bioreactor within its Mobius single-use platform in September 2024.
- —
Getinge's Applikon Biotechnology business introduced its SUPR production-scale single-use bioreactor in 2024.
- —
WuXi Biologics commenced construction of a commercial microbial manufacturing site in Chengdu, China in May 2025, spanning 95,000 square meters and featuring a 15,000-liter fermenter.
- —
The European Commission proposed the European Biotech Act on December 16, 2025, to complement the Critical Medicines Act and strengthen EU biotechnology research and manufacturing capacity.
- —
India's Department of Pharmaceuticals opened the fifth round of applications under its Production Linked Incentive Scheme for Bulk Drugs in 2025, targeting fermentation-based antibiotics including erythromycin, neomycin, and gentamicin.
- Sartorius AG · Germany
- Danaher Corporation/Cytiva (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Merck KGaA · Germany
- Eppendorf SE · Germany
- ABEC, Inc. (U.S.)
- Getinge AB · Sweden
- Tofflon Science and Technology Co., Ltd. · China
- GEA Group Aktiengesellschaft · Germany
- Pierre Guérin · France
- ZETA GmbH · Austria
- Bioengineering AG · Switzerland
- INFORS HT · Switzerland
- PBS Biotech, Inc. (U.S.)
- Solaris Biotech Solutions S.r.l · Italy
Frequently asked questions
The global biologics fermentation capacity market size is estimated at USD 9.85 billion in 2026.
Cite this report
Meticulous Research. (2026). Biologics Fermentation Capacity Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2165). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/biologics-fermentation-capacity-market-6848